Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

BTK
89011
with common variable immunodeficiency (CVID). As well, some BTK mutations can preserve small
numbers of circulating B cells and, therefore, all 3 of the criteria mentioned above need to be evaluated.
The preferred approach for confirming a diagnosis of XLA in males and identifying carrier females
requires testing for the Btk protein expression on B cells by flow cytometry and genetic testing for a BTK
mutation. Patients can be screened for the presence of Btk protein by flow cytometry (#89011 "Bruton's
Tyrosine Kinase [Btk], Protein Expression, Flow Cytometry, Blood"); however, normal results by flow
cytometry do not rule out the presence of a BTK mutation with normal protein expression but aberrant
protein function. The diagnosis is confirmed only in those individuals with appropriate clinical history
who have a mutation identified within BTK by gene sequencing or who have other male family members
with hypogammaglobulinemia with absent or low B cells.
Useful For: As a follow-up confirmatory genetic test for relatives of X-linked agammaglobulinemia
(XLA) patients with a previously identified Brutonâ€s tyrosine kinase gene (BTK) mutation, after
abnormal Btk protein expression has been previously demonstrated (eg, #89011 "Bruton's Tyrosine
Kinase (Btk), Protein Expression, Flow Cytometry, Blood") Because genotype-phenotype correlations
are important, the preferred test for confirming a diagnosis of XLA in males and identifying carrier
females in families where a BTK mutation has already been identified is #89740 "Bruton's Tyrosine
Kinase (BTK) Genotype and Protein Analysis, Known Mutation Sequencing and Flow Cytometry,"
which provides a comprehensive assessment of both protein and DNA analysis.
Interpretation: A patient-specific interpretive report is provided.
Reference Values:
An interpretive report will be provided.
Clinical References: 1. Tsukada S, Saffran DC, Rawlings DJ, et al: Deficient expression of a B
cell cytoplasmic tyrosine kinase in human X- linked agammaglobulinemia. Cell 1993 Jan
29;72(2):279-290 2. Noordzij JG, de Bruin-Versteeg S, Comans-Bitter WM, et al: Composition of
precursor B-cell compartment in bone marrow from patients with X-linked agammaglobulinemia
compared with healthy children. Pediatr Res 2002 Feb;51(2):159-168 3. Conley ME, Broides A,
Hernandez-Trujillo V, et al: Genetic analysis of patients with defects in early B-cell development.
Immunol Rev 2005 Feb;203:216-234 4. Lindvall JM, Blomberg KE, Valiaho J, et al: Brutonâ€s
tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and
expression profiling. Immunol Rev 2005 Feb;203:200-215 5. Valiaho J, Smith CI, Vihinen M:
BTKbase: the mutation database for X-linked agammaglobulinemia. Hum Mutat 2006
Dec;27(12):1209-1217 6. Takada H, Kanegane H, Nomura A, et al: Female agammaglobulinemia due
to the Bruton tyrosine kinase deficiency caused by extremely skewed X-chromosome inactivation.
Blood 2004 Jan 1;103(1):185-187
Bruton's Tyrosine Kinase (Btk), Protein Expression, Flow
Cytometry, Blood
Clinical Information: The differential diagnosis for patients with hypogammaglobulinemia of
unclear etiology (after other causes of hypogammaglobulinemia have been ruled out) includes common
variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA). CVID is the most
common diagnosis of a humoral immunodeficiency, particularly in children (2-8 years) and adults.
However, adult male patients with XLA may be misdiagnosed with CVID. XLA is an independent
humoral immunodeficiency and not a subset of CVID. XLA is the prototypical humoral
immunodeficiency and is caused by mutations in the BTK gene, which encodes Bruton's tyrosine kinase
(Btk), a hematopoietic-specific tyrosine kinase. XLA is characterized by reduced or absent Btk
expression on B cells, a significant reduction or absence of circulating B cells in blood and profound
hypogammaglobulinemia of all isotypes (IgG, IgA, IgM, and IgE). The clinical presentation includes
early onset of recurrent bacterial infections, and absent lymph nodes and tonsils. The vast majority of
XLA patients are diagnosed in childhood (median age of diagnosis in patients with sporadic XLA is 26
months), although some patients are recognized in early adulthood or later in life. The diagnosis of XLA
in both children and adults indicates that the disorder demonstrates considerable clinical variability
depending on the position of the mutations within the gene that determines the clinical severity of
Current as of January 3, 2013 2:22 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 307